CORT, LAKE, NAVN Face Shareholder Litigation Over Disclosure Failures

Three publicly traded companies—Corcept Therapeutics Incorporated ($CORT), Lakeland Industries, Inc. ($LAKE), and Navan, Inc. ($NAVN)—are facing shareholder class action lawsuits alleging material misstatements and incomplete disclosures, according to announcements by law firm Holzer & Holzer, LLC. The litigation targets allegedly false or misleading statements spanning clinical trial data, business operations, and sales and marketing expenses, with lead plaintiff deadlines set for April 2026. Investors who purchased shares during specified class periods and sustained losses are being encouraged to pursue lead plaintiff status ahead of the court-imposed deadlines.

The Allegations and Legal Framework

The three separate lawsuits allege distinct categories of corporate misconduct, each carrying significant implications for shareholder confidence and corporate governance:

Corcept Therapeutics ($CORT) faces allegations centered on materially false statements and omissions regarding its clinical trial data. As a pharmaceutical company heavily dependent on clinical evidence to support drug efficacy claims and regulatory approvals, misrepresentations about trial results could have material impacts on:

• Drug approval timelines and regulatory compliance
• Revenue projections and commercial viability
• Shareholder valuations tied to pipeline success

Lakeland Industries ($LAKE), a protective equipment and clothing manufacturer, is defending against claims of failures to disclose material facts related to its core business operations. Such disclosures typically encompass supply chain disruptions, manufacturing capacity, quality control issues, or demand forecasting problems—any of which could substantially affect operational performance and profitability.

Navan, Inc. ($NAVN), a travel and expense management software provider, faces allegations regarding undisclosed or misrepresented sales and marketing expenses. The transparency of customer acquisition costs, marketing spend efficiency, and go-to-market strategy is crucial for SaaS and software companies, where investor assessment of growth sustainability and unit economics depends heavily on accurate expense reporting.

Investor Response and Legal Process

Shareholder class action litigation has become an increasingly common mechanism for investor protection when companies face allegations of disclosure failures. The lead plaintiff process is a formal procedure governed by the Private Securities Litigation Reform Act (PSLRA), which requires:

• Identification of investors with the largest financial stakes in the litigation
• Court certification of lead plaintiffs who can represent the broader shareholder class
• Filing of detailed complaints establishing material misstatement and investor reliance

With deadlines scheduled for April 2026, shareholders who meet the class period requirements have a limited window to demonstrate their standing and pursue leadership roles in the litigation. Lead plaintiffs typically work closely with counsel to shape discovery, settlement negotiations, and potential monetary recoveries.

The specified class periods for each company define the window during which shareholders must have purchased shares to qualify for the litigation. These periods are typically established to encompass the timeframe during which the alleged misstatements or omissions occurred and affected share prices.

Market Context: Sector Vulnerabilities and Regulatory Pressures

These simultaneous lawsuits reflect broader challenges facing their respective industries:

Pharmaceutical and Biotech Sector ($CORT): Companies in this space face heightened scrutiny over clinical trial transparency, following years of regulatory enforcement actions and investor skepticism. The FDA and institutional investors increasingly demand rigorous disclosure of trial methodologies, adverse events, and preliminary efficacy data. Misstatements about clinical endpoints can trigger sharp stock price declines and regulatory consequences.

Industrial and Protective Equipment ($LAKE): This sector experienced significant volatility post-pandemic as demand normalization, supply chain stabilization, and competitive pressures reshaped market dynamics. Operational transparency became critical as investors reassessed business resilience and growth prospects in a normalized environment.

Enterprise Software and Travel Management ($NAVN): SaaS companies face persistent investor demands for clarity on customer retention, churn rates, and the efficiency of customer acquisition spending. The sector has experienced multiple instances of guidance misses and expense restatements, elevating investor sensitivity to disclosure quality.

Investor Implications and Stock Price Risk

Shareholder litigation typically indicates investor losses and reputational damage that extend beyond legal settlements. The implications include:

• Stock Price Volatility: Class action announcements often precede or accompany stock price declines as investors price in litigation risk and potential settlements
• Governance Concerns: Allegations of disclosure failures raise questions about internal controls, audit committee effectiveness, and management credibility
• Settlement Costs: Defense and settlement expenses can reach millions of dollars, impacting profitability and capital allocation
• Regulatory Scrutiny: Litigation frequently triggers parallel investigations by the SEC or state regulators, adding compliance costs
• Institutional Investor Relations: Institutional shareholders and index funds may reassess their positions based on corporate governance concerns

Investors holding positions in $CORT, $LAKE, or $NAVN should monitor:

• SEC filings for disclosures related to the litigation
• Quarterly earnings calls for management commentary on legal proceedings
• Potential settlement announcements that could impact cash balances
• Any restatements or corrective disclosure amendments

Looking Ahead: The Path Forward

As the April 2026 deadlines approach, the litigation process will advance through multiple stages: lead plaintiff certification, motion to dismiss rulings, discovery, and potential settlement negotiations. Outcomes could range from early dismissals on legal grounds to significant monetary settlements funded by the defendants' insurance or cash reserves.

For shareholders considering lead plaintiff status, the decision requires careful assessment of individual loss calculations, risk tolerance, and commitment to the litigation timeline. Legal counsel specializing in securities litigation can provide guidance on eligibility and potential recovery scenarios.

These three cases underscore the persistent challenge of corporate disclosure accuracy in complex industries where investors depend on transparent, timely information to make informed capital allocation decisions. The shareholder lawsuit mechanism remains a critical check on corporate governance, even as companies and regulators grapple with evolving standards for what constitutes material disclosure in rapidly changing business environments.